Anti-tumor necrosis factor agents in sarcoidosis: A systematic review of efficacy and safety

Though anti-tumor necrosis factor agents (anti-TNFs) have been recommended as third-line therapy for sarcoidosis, an up-to-date systematic synthesis of their efficacy and safety is lacking. To systematically review the literature to characterize the efficacy and safety of anti-TNFs in sarcoidosis. A...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Seminars in arthritis and rheumatism 2019-06, Vol.48 (6), p.1093-1104
Hauptverfasser:	Adler, Brandon L., Wang, Catherine J., Bui, Thanh-Lan, Schilperoort, Hannah M., Armstrong, April W.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab Etanercept Humans Infliximab Sarcoidosis Sarcoidosis - drug therapy Therapeutics Treatment Outcome Tumor Necrosis Factor Inhibitors - adverse effects Tumor Necrosis Factor Inhibitors - therapeutic use Tumor necrosis factor-alpha
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!